Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.
Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs). This report contains market size and forecasts of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in global, including the following market information:
- Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market was valued at US$ 14800 million in 2022 and is projected to reach US$ 54520 million by 2029, at a CAGR of 20.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.
We surveyed the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Segment Percentages, by Type, 2022 (%)
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Segment Percentages, by Application, 2022 (%)
- Breast Cancer Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Colorectal Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Other Cancers Diagnosis and Treatment
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) revenues share in global market, 2022 (%)
- Further, the report presents profiles of competitors in the market, key players include:
- Janssen
- Qiagen
- Advanced Cell Diagnostics
- ApoCell
- Biofluidica
- Clearbridge Biomedics
- CytoTrack
- Celsee
- Fluxion
- Gilupi
- Cynvenio
- On-chip
- YZY Bio
- BioView
- Fluidigm
- Ikonisys
- AdnaGen
- IVDiagnostics
- Miltenyi Biotec
- ScreenCell
- Silicon Biosystems
- Outline of Major Chapters:
- Chapter 1: Introduces the definition of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), market overview.
- Chapter 2: Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size in revenue.
- Chapter 3: Detailed analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
- Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 6: Sales of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
- Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
- Chapter 8: The main points and conclusions of the report.
